TGFB1 and cancer: In addition, LY364947, a TGF-β inhibitor, was used in a mesoporous silica-based NP to reduce pericyte coverage of cancer vessels and thus enhance the delivery of gemcitabine, contained in a liposome-based NP, in a mouse model of PC which resulted in decreased tumor growth (Meng et al., 2013).